high-grade B-cell lymphoma double-hit/triple-hit
Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:0081004
Name high-grade B-cell lymphoma double-hit/triple-hit
Definition A large B-cell lymphoma that is characterized by the abnormal rearrangement of two genes, MYC gene and either BCL2 or BCL6 genes.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma large B-cell lymphoma high-grade B-cell lymphoma double-hit/triple-hit

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03696784 Phase I Rimiducid Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma Active, not recruiting USA 0
NCT04002947 Phase II Acalabrutinib + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma Recruiting USA 0
NCT04231877 Phase I Cyclophosphamide + Doxorubicin + Etoposide + Glofitamab-gxbm + Polatuzumab vedotin-piiq + Prednisone + Rituximab Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma Recruiting USA 0
NCT04479267 Phase II Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisolone + Rituximab Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab Cyclophosphamide + Doxorubicin + Methylprednisolone + Polatuzumab vedotin-piiq + Rituximab Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma Active, not recruiting USA 0
NCT04855253 Phase Ib/II E7777 Study of E7777 Prior to Kymriah for R/R DLBCL Recruiting USA 0
NCT04970901 Phase I Obinutuzumab Loncastuximab tesirine-lpyl + Mosunetuzumab-axgb Loncastuximab tesirine-lpyl + Polatuzumab vedotin-piiq Glofitamab-gxbm + Loncastuximab tesirine-lpyl A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) Recruiting USA | ITA | GBR | ESP | CZE | BEL 0
NCT05400109 Phase I Cyclophosphamide + Fludarabine UF-KURE19 Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas Recruiting USA 0
NCT05507541 Phase II Pembrolizumab + TTI-622 Pembrolizumab + TTI-621 TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Active, not recruiting USA 0
NCT05600686 Phase II Cyclophosphamide + Doxorubicin + Etoposide + Loncastuximab tesirine-lpyl + Prednisone + Rituximab + Vincristine Sulfate Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma Recruiting USA 0
NCT05641428 Phase II axicabtagene ciloleucel ARI-0001 Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL (HOVON161) Recruiting NLD 0
NCT05664217 Phase II NKTR-255 NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma Terminated USA 0
NCT05755087 Phase I Tegavivint Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma Recruiting USA 0
NCT05852717 Phase II Cisplatin + Dexamethasone + Epcoritamab-bysp + Gemcitabine Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma Recruiting USA 0
NCT05929716 Phase II Magrolimab + Rituximab An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma Withdrawn 0
NCT05989204 Phase I HuCART19-IL18 TmCD19-IL18 in CD19+ Cancers Recruiting USA 0
NCT06045247 Phase II Cyclophosphamide + Epcoritamab-bysp + Prednisone + Rituximab + Vincristine Sulfate Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma Recruiting USA 0
NCT06088654 Phase Ib/II IPH6501 Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma Recruiting USA | FRA | AUS 0
NCT06090539 Phase I BMS-986458 + Rituximab BMS-986458 BMS-986458 + Mosunetuzumab-axgb BMS-986458 + Glofitamab-gxbm + Obinutuzumab A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas Recruiting USA | NLD | FRA | ESP | DEU | CHE 0
NCT06248086 Phase I ASP101G + ASP2802 A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas Terminated AUS 0
NCT06287398 Phase II Epcoritamab-bysp Cytarabine + Dexamethasone + Epcoritamab-bysp + Oxaliplatin + Rituximab Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL Recruiting AUS 0
NCT06649812 Phase II Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma Recruiting USA 0
NCT06788964 Phase II Loncastuximab tesirine-lpyl + Rituximab Loncastuximab Tesirine and Rituximab as Bridging Therapy Prior to Standard-of-care CD19 CAR T-cell Therapy in Patients With Large B-cell Lymphoma (CORAL) Recruiting USA 0
NCT06905509 Phase II Cytarabine + Dexamethasone + Epcoritamab-bysp + Oxaliplatin + Rituximab Epcoritamab-bysp + Gemcitabine + Oxaliplatin Carboplatin + Cytarabine + Dexamethasone + Epcoritamab-bysp + Rituximab Carboplatin + Epcoritamab-bysp + Etoposide + Ifosfamide + Rituximab Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Recruiting USA 0
NCT06918912 Phase II Loncastuximab tesirine-lpyl Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure (LORELY) Recruiting ITA 0
NCT06919939 Phase II Epcoritamab-bysp + Loncastuximab tesirine-lpyl Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma (EPCOR+LONCA) Not yet recruiting USA 0
NCT06977711 Phase I Loncastuximab tesirine-lpyl + Rituximab + Roflumilast Cyclophosphamide + Doxorubicin + Loncastuximab tesirine-lpyl + Prednisone + Rituximab + Vincristine Sulfate Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL) Recruiting USA 0
NCT07042438 Phase II Fecal microbiota axicabtagene ciloleucel + Fecal microbiota Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells Not yet recruiting USA 0
NCT07082803 Phase I TLN-121 + TLN-254 TLN-121 TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas Recruiting USA | AUS 0
NCT07097363 Phase II Cyclophosphamide + Doxorubicin + Epcoritamab-bysp + Etoposide + Prednisone + Rituximab Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma Not yet recruiting USA 0
NCT07123454 Phase Ib/II AZD4512 A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (Lumi-NHL) Recruiting USA | ITA | GBR | AUS 3
NCT07166549 Phase I Anti-CD19-CD20 CAR T cells Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial) (BaseCAR-01) Not yet recruiting CHE 0
NCT07197307 Phase II Epcoritamab-bysp + Loncastuximab tesirine-lpyl Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) (CLEAR) Not yet recruiting DEU 0
NCT07225439 Phase I Aldesleukin + Rituximab + Tafasitamab-cxix Cyclophosphamide + Fludarabine Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Not yet recruiting USA 0
NCT07226843 Phase I LY4584180 + Rituximab LY4584180 A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers Not yet recruiting USA 0
NCT07254754 Phase II axicabtagene ciloleucel Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma (LATE-R-GEL-23) Recruiting ESP 0